CA-XPRIZE
23.6.2021 19:32:08 CEST | Business Wire | Press release
XPRIZE , the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, and IBM Watson , IBM’s AI technology for business, today announced the Grand Prize Winner in the $5M IBM Watson AI XPRIZE Challenge . First launched in 2016, the five-year global competition looked to accelerate adoption of artificial intelligence (AI) technologies and spark creative, innovative and audacious demonstrations of the technology that are truly scalable to solve societal grand challenges.
Winning first place honors is Zzapp Malaria , in second place is Aifred Health , followed by Marinus Analytics . These finalists were selected out of a pool of 10 semifinalists following presentations of their solutions to a panel of judges during an event held at TED headquarters in New York City last year. A $3 million grand prize, $1 million second place prize, and $500k third place prize will be awarded to the teams. In total, over 150 teams throughout the world joined the competition.
"After five years of hard work and dedication, XPRIZE is thrilled to announce Zzapp Malaria as the grand prize winner of IBM Watson AI XPRIZE,” said Anousheh Ansari, CEO of XPRIZE. “Zzapp Malaria, Aifred Health and Marinus Analytics are on the forefront of AI advancement, and we are looking forward to seeing firsthand the positive impact they will have on our future.”
"Each of the three finalists of the IBM Watson AI XPRIZE showcase what's possible when the power of AI is used to address some of the world’s toughest challenges,” said Daniel Hernandez, General Manager, IBM Data and AI. “It’s inspiring to witness how the AI technologies we developed at IBM help these organizations realize and scale their good tech solutions to drive positive societal change.”
Based out of Tel Aviv, Israel, Zzapp Malaria is committed to malaria elimination. The team’s AI technology is geared towards tackling the main challenges faced by malaria elimination campaigns by creating custom models, built with tools like IBM Watson Studio for Cloud Pak for Data, to predict the number of small water bodies caused by weather, enabling it to optimize the timing for launching larviciding operations.
- Marinus Analytics (based out of Pittsburgh, PA): A woman-owned company founded in 2014 out of Carnegie Mellon Robotics that is driven by a single social mission: To fight human trafficking. Their solution, Traffic Jam, is a suite of analytics tools that saves hours and sometimes days of investigative time to find traffickers and recover victims by quickly turning big data into actionable intelligence. Marinus Analytics has used IBM Watson Discovery and IBM Watson Assistant to extend their Traffic Jam application, aiding investigation into financial fraud and the illicit flow of proceeds to international crime groups.
- Aifred Health (based out of Montreal, Canada): A digital health company focused on clinical decision support in mental health, starting with depression. The team’s solution uses AI to learn from thousands of patients to help tailor treatment, reducing the time it takes for a patient to reach remission. IBM Watson Health is providing Aifred Health with millions of records of observational depression data to improve their ML models.
To determine the winner, XPRIZE AI convened a global jury of representatives from around the world. The jury evaluated each team based on their performance in the following four dimensions: achieved technical impact, evidenced real-world impact, scalability of real-world impact, and ethics and safety.
The winning teams were announced today in partnership with WIRED during the IBM Watson AI XPRIZE’s AI For Good fireside chat featuring Anousheh Ansari, CEO of XPRIZE, and Seth Dobrin, IBM’s Chief AI Officer. The two discussed the challenge and the importance of AI for the future of humanity. As part of their partnership with WIRED, XPRIZE opened up a public vote for the Most Inspiring Team, and Zzapp Malaria was selected as the winner. You can watch the full fireside chat and view additional content via WIRED’s content hub linked here.
About XPRIZE
XPRIZE, a 501(c)(3) nonprofit organization, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100M XPRIZE Carbon Removal, $15M XPRIZE Feed the Next Billion, $10 Million XPRIZE Rainforest, $10 Million ANA Avatar XPRIZE and $5 Million XPRIZE Rapid Reskilling. For more information, visit xprize.org.
About IBM Watson
Watson is IBM’s AI technology for business, helping organizations to better predict and shape future outcomes, automate complex processes, and optimize employees’ time. Watson has evolved from an IBM Research project, to experimentation, to a scaled, open set of products that run anywhere. With more than 40,000 client engagements, Watson is being applied by leading global brands across a variety of industries to transform how people work. To learn more, visit: https://www.ibm.com/watson .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005848/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom